

VGI Health Technology Limited – FY24 Financial Report

Sydney, New South Wales, 16 September 2024 – Due to the Management Team and the directors needing to address urgent issues that have arisen, the Company did not lodge a Preliminary Financial Report on 13 September 2024 as required by the NSX Listing Rules. The Company is currently working with its auditors to lodge its 2024 Annual Report, including the audited Financial Statements and Remuneration Report for FY24, no later than 30 September 2024.

This announcement was authorised for release by the Board of the Company.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:

https://www.nsx.com.au/broker_list_print.asp